TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32046415
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate treatment
Study: 32046415
Drug: Cetrorelix treatment
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix treatment
Study: 34536714
Drug: Cognitive Anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Anxiety Sensitivity Treatment (CAST)
Study: 32240476
Drug: MDGP external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDGP external umbilicus treatment, twice a week for 4 weeks.
Study: 32240476
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group, twice a week for 4 weeks.
Study: 32167484
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg daily for 8 weeks before HoLEP
Study: 33150816
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (MAS) extended-release
Study: 32981933
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink (fermented milk containing Lactobacillus casei strain Shirota) 65 mL/day with 108 CFU/mL for 12 weeks
Study: 32339234
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing and tailored counselling on medication adherence
Study: 34485522
Drug: Molecular docking
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular docking analysis of compound STOCK2S-23597
Study: 36233791
Drug: Cognitive-Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavior Therapy delivered by Videoconference (VCP)
Study: 36233791
Drug: Face-to-Face Cognitive-Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-Face Cognitive-Behavior Therapy
Study: 36233791
Drug: Cognitive-Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavior Therapy (both VCP and Face-to-Face)
Study: 34000628
Drug: Prolonged release-fampridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release-fampridine (10 mg b.i.d.)
Study: 33234137
Drug: Downstream administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Downstream administration of prasugrel
Study: 33234137
Drug: Downstream administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Downstream administration of ticagrelor
Study: 32416251
Drug: Preventive anti-rash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive anti-rash medication
Study: 35834812
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg HPV‐6/11 vaccine
Study: 35834812
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg HPV‐6/11 vaccine
Study: 35834812
Drug: 90 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 μg HPV‐6/11 vaccine
Study: 35834812
Drug: HPV‐6/11 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐6/11 vaccine (all doses)
Study: 35834812
Drug: HPV‐6/11 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐6/11 vaccine
Study: 35241271
Drug: Initial opioid
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial opioid prescription for low-pain procedures
Study: 35241271
Drug: Initial opioid
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial opioid prescription for moderate-pain procedures
Study: 35241271
Drug: Initial opioid
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial opioid prescription for high-pain procedures
Study: 32921508
Drug: Blank patches
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank patches (Control)
Study: 33854301
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus before induction, followed by 2.0 mg/kg/h until end of operation)
Study: 34851799
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg subcutaneously
Study: 35436816
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban (10mg or 15mg)
Study: 35436816
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin (40mg or 60mg)
Study: 32147955
Drug: Sildenafil (PDE5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (PDE5 inhibitor)
Study: 35533340
Drug: Pi/D (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pi/D (conventional therapy)
Study: 35409861
Drug: Postoperative co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative co-amoxiclav (625 mg)
Study: 35409861
Drug: Preoperative co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative co-amoxiclav (625 mg) plus postoperative metronidazole (500 mg)
Study: 35409861
Drug: Preoperative co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative co-amoxiclav (625 mg) plus postoperative amoxicillin (500 mg)
Study: 35781804
Drug: IPE 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPE 2.0 g/day (1×1 g twice daily) for 28 days
Study: 35781804
Drug: IPE 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPE 4.0 g/day (2×1 g twice daily) for 28 days
Study: 34578893
Drug: secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 300 mg plus a tailored lifestyle intervention program
Study: 32738817
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment for stress urinary incontinence
Study: 34581002
Drug: MTPS9579A (dissociating
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTPS9579A (dissociating anti-tryptase antibody) administered subcutaneously (s.c.) or intravenously (i.v.) in single and multiple ascending doses.
Study: 34797296
Drug: Shaobei injection
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shaobei injection
Study: 33557701
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser extirpation with methyl aminolevulinate photodynamic therapy
Study: 34657371
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 130/0.4 (HES) at 10 mL/kg
Study: 34657371
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline 7.5% (HS) at 4 mL/kg
Study: 32538466
Drug: Fluconazole 5
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 5 mg kg‐1 per day
Study: 32538466
Drug: Griseofulvin 10
Normalized name: griseofulvin 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 10 mg kg‐1 per day
Study: 32538466
Drug: Itraconazole 5
Normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 5 mg kg‐1 per day
Study: 32538466
Drug: Terbinafine 7·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 7·5 mg kg‐1 per day
Study: 34238688
Drug: Iodine-125 Low-Dose-Rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-125 Low-Dose-Rate brachytherapy
Study: 32877599
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib (150 mg twice daily and 2 mg once daily respectively)
Study: 32657670
Drug: Antrodia cinnamomea
Normalized name: Antrodia cinnamomea fruiting body
DrugBank: Taiwanofungus camphoratus fruiting body (DB19272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antrodia cinnamomea mycelium (ACM), 420 mg, three capsules per day for 6 months
Study: 32657670
Drug: Placebo (starch),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch), 420 mg, three capsules per day for 6 months
Study: 35840352
Drug: Control (guideline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (guideline-based medical therapy)
Study: 34929392
Drug: Sugarcane bagasse
Normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugarcane bagasse diet (33 g/d fiber)
Study: 34929392
Drug: Fiber combination
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber combination diet (sugarcane bagasse with resistant starch, 45 g/d fiber)
Study: 33002647
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy with reduced treatment volumes (50.4 Gy total radiation dose, fluoropyrimidine‐based chemotherapy)
Study: 33002647
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy with reduced treatment volumes
Study: 33650767
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) session per month and three home exercise sessions per week for four months
Study: 38729636
Drug: Spironolactone 25-50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25-50 mg/day
Study: 33947363
Drug: Ibandronate treatment
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate treatment for osteoporosis alone (Group 1)
Study: 33947363
Drug: Ibandronate treatment
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate treatment for osteoporosis with symptomatic LSS (Group 2)
Study: 34742917
Drug: Multi-interventional approach
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-interventional approach for medication safety (MIMS) including medication reconciliation at admission and discharge, medication review, and standardized transmission of medication changes to community practitioners.
Study: 34742917
Drug: Multi-interventional approach
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-interventional approach for medication safety (MIMS)
Study: 37188468
Drug: Caffeine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 1.5 mg/kg
Study: 32178928
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with inhaled anesthetic
Study: 34979544
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU of intranasal oxytocin (IN-OT)
Study: 38297337
Drug: Vi-DT vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-DT vaccine
Study: 35879015
Drug: Bariatric surgery
Normalized name: Optisource Post Bariatric Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bariatric surgery and intensive goal-directed medical therapy
Study: 33761182
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to medication management systems
Study: 34368187
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg intravenous)
Study: 34368187
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg intravenous) during hypoxia
Study: 34417198
Drug: tivozanib 1.34
Normalized name: tivozanib 1.34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tivozanib 1.34 mg orally once daily for 21 consecutive days of every 28‐day cycle
Study: 34417198
Drug: sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 400 mg orally twice daily continuously
Study: 33766814
Drug: Medroxyprogesterone Acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone Acetate (MPA) 400 mg intramuscularly on day 1
Study: 33766814
Drug: Medroxyprogesterone Acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone Acetate (MPA) 400 mg intramuscularly on day 1 plus Entinostat 5 mg orally on days 1, 8, and 15
Study: 36154103
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with statin and ezetimibe
Study: 36154103
Drug: Higher target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher target group (LDL cholesterol of 100±10 mg/dL)
Study: 32640956
Drug: Fenugreek vaginal
Normalized name: FENUGREEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek vaginal cream 5% (0.5g, twice a week for 12 weeks)
Study: 32640956
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens vaginal cream (0.625 mg, containing 0.3 mg of conjugated estrogens)
Study: 36088292
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of MATRix (control treatment)
Study: 36088292
Drug: Pre-phase (R/HD-MTX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-phase (R/HD-MTX) followed by 2 cycles of MATRix (experimental treatment)
Study: 32639518
Drug: Evacetrapib, 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib, 130 mg/d
Study: 32804742
Drug: Pimavanserin 34
Normalized name: pimavanserin 34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin 34 mg daily added to ongoing antidepressant therapy
Study: 616926927
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg IV
Study: 616926927
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg IV
Study: 34273258
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet of metformin hydrochloride/vildagliptin 850 mg/50 mg (test preparation)
Study: 34273258
Drug: Branded product
Normalized name: Eagle Brand Medicated Oil Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded product of metformin hydrochloride/vildagliptin 850 mg/50 mg (reference preparation)
Study: 33346814
Drug: BoNT injection
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT injection
Study: 33966115
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses > 40 Gy
Study: 33966115
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses > 50 Gy
Study: 33966115
Drug: Radiotherapy doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy doses > 60 Gy
Study: 34715031
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (900 mg daily for 6 months)
Study: 32162804
Drug: vanucizumab 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: vanucizumab 2,000 mg plus mFOLFOX-6
Study: 32162804
Drug: bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab 5 mg/kg plus mFOLFOX-6
Study: 35445567
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel (up to 12 mg/day)
Study: 34153968
Drug: Low-dose alteplase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alteplase (0.6 mg/kg)
Study: 34153968
Drug: Standard-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose alteplase (0.9 mg/kg)
Study: 32175655
Drug: Efpeglenatide (2-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide (2-100 μg/kg single dose)
Study: 32175655
Drug: Efpeglenatide (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide (1, 2, or 4 mg once weekly for 8 weeks; 8, 12, or 16 mg once monthly for 9 weeks)
Study: 32175655
Drug: Efpeglenatide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide (various doses)
Study: 32803573
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab
Study: 35268154
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg kg−1 plus ropivacaine 0.5% (MR0.5%)
Study: 35268154
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg kg−1 plus ropivacaine 0.35% (MR0.35%)
Study: 35268154
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg kg−1 plus ropivacaine 0.25% (MR0.25%)
Study: 32960654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ascites code with a code for chronic liver disease
Study: 32107571
Drug: D2/D3 dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2/D3 dopamine agonist (pramipexole)
Study: 33856733
Drug: Crocin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (15 mg twice daily)
Study: 32222135
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice daily) plus aspirin
Study: 35550342
Drug: Femoral, sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral, sciatic and obturator nerve blocks (group FSO) [n = 50; ropivacaine 0.75% (0.75 mg kg–1)]
Study: 35550342
Drug: Femoral, sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral, sciatic and placebo (group FSP) [n = 50; ropivacaine 0.75% (0.75 mg kg–1) and saline solution 0.9% (0.1 mL kg–1)]
Study: 35879610
Drug: Urate-lowering therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urate-lowering therapy
Study: 34592164
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg once a day for 24 weeks) + ivGCs (methylprednisolone 500 mg once a week for 6 weeks followed by 250 mg once a week for an additional six weeks)
Study: 34592164
Drug: ivGCs (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivGCs (methylprednisolone 500 mg once a week for 6 weeks followed by 250 mg once a week for an additional six weeks)
Study: 32070323
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D vaginal suppository (1000 units of vitamin D3)
Study: 33483132
Drug: Phenylephrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (0.5 μg kg‐1 min‐1)
Study: 33483132
Drug: Phenylephrine (30-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (30-50 μg kg‐1 min‐1) in mice
Study: 34563273
Drug: Adjuvant atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant atezolizumab after adjuvant chemotherapy
Study: 35326659
Drug: Topical bimiralisib
Normalized name: Bimiralisib
DrugBank: Bimiralisib (DB14846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bimiralisib 2.0% gel
Study: 33957642
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate
Study: 32797473
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg/2 weeks intramuscularly)
Study: 35168477
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment approaches
Study: 34328024
Drug: Home-based electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based electrical stimulation (E-Stim) therapy for 1 hour daily for 4 weeks
Study: 32579785
Drug: MA formulation
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MA formulation (3.75 μg HA + AS03 adjuvant system)
Study: 32579785
Drug: MB formulation
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB formulation (3.75 μg HA + 1/2AS03)
Study: 32579785
Drug: HA formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA formulation (7.5 μg HA + AS03)
Study: 32579785
Drug: HB formulation
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB formulation (7.5 μg HA + 1/2AS03)
Study: 33892684
Drug: Rumination-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumination-focused cognitive behavioral therapy (RFCBT)
Study: 36058950
Drug: Intratesticular (IT)
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratesticular (IT) administration of 10 mg/kg ZT
Study: 36058950
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of 10 mg/kg ZT
Study: 34103426
Drug: Amplipulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amplipulse therapy (modulated sinusoidal currents)
Study: 33467603
Drug: Global postural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global postural re-education (GPR) therapy session (10 min session)
Study: 35189943
Drug: TLC599 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC599 12 mg
Study: 35189943
Drug: TLC599 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC599 18 mg
Study: 34496979
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg/week plus Methotrexate (MTX)
Study: 34613513
Drug: Osmotic Release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic Release Oral System (OROS) Methylphenidate (MPH)
Study: 32066605
Drug: Brief support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief support for self-management of weight during child immunisation appointments, including weekly self-weighing and use of an online weight management programme.
Study: 616850836
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg genistein daily for 3-6 weeks before prostatectomy